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Summary The products of ras and src proto-oncogenes are frequently activated in a constitutive state in
human colorectal cancer. In this study we attempted to establish whether the tumorigenic progression induced
by oncogenic activation of p21'as and pp6Ocsrc in human colonic Caco-2 cells is associated with specific
alterations of syndecan-1, a membrane-anchored proteoglycan playing a role in cell-matrix interaction and
neoplastic growth control. To this end, we used Caco-2 cells made highly tumorigenic by transfection with an
activated (Val 12) human Ha-ras gene or with the polyoma middle T (Py-MT) oncogene, a constitutive
activator of pp6Oc-src tyrosine kinase activity. Compared with control vector-transfected Caco-2 cells, both
oncogene-transfected cell lines (1) contained smaller amounts of membrane-anchored PGs; (2) exhibited
decreased syndecan-1 expression at the protein but not the mRNA level; (3) synthesised 35S-labelled syndecan-1
with decreased specific activity; (4) produced a syndecan-1 ectodomain with a lower molecular mass and
reduced GAG chain size and sulphation; and (5) expressed heparanase degradative activity. These results show
that the dramatic activation of the tumorigenic potential induced by oncogenic p2l" or Py-MT/pp60csrc in
Caco-2 cells is associated with marked alterations of syndecan-1 expression at the translational and post-
translational levels.
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Human colorectal cancer, the second most common cause of
death in developed countries, is now thought to result from a
series of genetic alterations. The most frequent alterations
consist of point mutations in members of the ras gene family
(Bos et al., 1987) which encode closely related Mr 21 000
guanine nucleotide-binding proteins (p2lIr-S) or in activation
of the pp6O phosphoprotein encoded by the proto-oncogene
c-src (Bolen et al., 1987; Cartwright et al., 1990). The high
frequency of these alterations strongly suggests that p2Iras
and pp6oc-src oncoproteins, both of which are involved in
growth factor signal transduction pathways, play a central
role in human colon carcinogenesis.
Cell transformation is frequently associated with specific
defects in the basement membrane, which play a critical role
in tumour growth, invasion and metastasis (Liotta et al.,
1986; Yamada, 1983). These defects result mainly from the
presence of specific enzymes involved in degradation of
extracellular matrix constituents (Matrisian, 1992), and also
from significant modifications in cell surface proteoglycans
(PGs) (lozzo, 1985). Specific qualitative and quantitative
changes in PGs have been reported in various transformed
cells. We previously demonstrated that the expression of PGs
alters considerably in intestinal epithelial cells after oncogene
immortalisation, representative of an early stage of neoplastic
transformation (Levy et al., 1990). Elevated concentrations of
hyaluronic acid have been demonstrated in breast carcinomas
and human gliomas (Glimelius et al., 1978), and increased
amounts of chondroitin sulphate (CS) PGs have been shown
in cancer cells from liver (Kojima et al., 1975) and in colon
cancer (lozzo and Wight, 1982). Transformed cells are known
to exhibit a reduced amount of undersulphated heparan
sulphate (HS) (Winterbourne and Mora, 1978) and some
authors have suggested that there is a relationship between
decreased HS content and increased activity of heparanase,
an enzyme which specifically degrades HS chains (Ricoveri
and Capelleti, 1986; Nakajima et al., 1984). Such alterations
in the amount and degree of sulphation of HS may help to
reduce cell matrix adhesion and thus favour tumour cell
shedding from primary tumours (lozzo, 1988).
Among the HS PGs, the syndecans, which constitute most
of the transmembrane PGs, appear to have a profound
influence on fundamental features of cell behaviour such as
adhesion, matrix anchorage and growth control (David,
1993). The syndecan family consists of at least four members
that differ considerably in their extracellular domains but
exhibit high degrees ofhomology in their transmembrane and
cytoplasmic domains (Bernfield et al., 1992; Rapraeger,
1993). Syndecan-1, which is found mainly on the surfaces
of epithelial cells in mature tissues, is the one that has been
most thoroughly characterised so far (Saunders et al., 1989).
It plays a key role in the maintenance of the epithelial cell
phenotype by anchoring cytoskeletal actin to the extracellular
matrix (ECM) (Rapraeger et al., 1986) and behaves like a
matrix receptor, by binding to a variety of ECM components
(Saunders and Bernfield, 1988; Sanderson et al., 1992a).
Despite the importance of the interaction between trans-
formed cells and the surrounding matrix as a regulatory
factor controlling the growth of these cells, there are only a
few studies dealing with the effects of malignant transforma-
tion on syndecan-1. Loss of syndecan-1 expression occurs in
experimental tumours induced by UV-irradiation of murine
skin (Inki et al., 1991), by glucocorticoid exposure of mouse
mammary epithelial cells (Leppa et al., 1991; Kirjavainen et
al., 1993) and in the malignant transformation of human
keratinocytes (Inki et al., 1994).
However, there is to our knowledge, no information about
the changes of syndecan-1 associated with ras and src
oncogene-mediated neoplastic colorectal transformation. To
address this issue, we used human colon carcinoma cells
Caco-2 which had been transfected with a plasmid vector
recombined either with an activated (Val 12) human c-Ha-ras
gene (Caco-2-T cells), or with the cDNA encoding the Py-MT
antigen, a constitutive activator of the tyrosine kinase of
pp6Oc-src (Caco-2 MT cells). Since parental Caco-2 cells are
known to display a very low tumorigenicity (Rousset et al.,
1980; Trainer et al., 1988), these ras- and Py-MT-transfected
Caco-2 cells, recently shown to be highly tumorigenic in nude
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mice (Chastre et al., 1993; Delage et al., 1993), provide very
suitable models in which the two defects most frequently
observed in human colon cancer are reproduced. In this
study, we investigated whether the tumorigenic progression
induced by oncogenic p21Izas or Py-MT/pp60c-src in Caco-2
cells was associated with (1) a change in syndecan-l
expression; (2) alterations in syndecan-1 ectodomain glyco-
sylation and sulphation; and (3) the expression of specific
endoglycosidase degradative activity.
Materials and methods
Materials
Carrier-free Na235SO4 (270 mCi mmol-') was purchased
from New England Nuclear, Boston, MA, USA. Chondroi-
tin ABC lyase (EC 4.2.2.4) was obtained from Seikagaku
Fine Chemicals, Tokyo, Japan. PD-10 columns, Sepharose
CL-4B and Sepharose CL-6B were obtained from Pharmacia
Fine Chemicals, Uppsala, Sweden. DEAE-Sephacel was
from Whatman Biochemicals, Maidstone, Kent, UK.
3 - [3 - cholamido propyl)dimethyl -ammonio] - 1 - propane -
sulphonate (CHAPS), phenylmethylsulphonyl fluoride
(PMSF), N-ethylmaleimide (NEM) and benzamidine were
from Calbiochem, San Diego, USA. Soybean trypsin
inhibitor was from Sigma Chemical Company, St Louis,
Missouri. Zeta-probe membranes were from Bio-Rad
Laboratories, Richmond, USA and Immobilon-N mem-
branes from Millipore, Bedford, MA, USA. All other
reagents, obtained from Boehringer Mannheim, Indianapo-
lis, IN, USA, were of the highest analytical grade.
Cell lines
Human colon carcinoma cells Caco-2 were transfected by
electroporation, as previously described (Chastre et al., 1993).
Homer 6, a plasmid vector containing a MoMSVLTR-driven
G418 resistance gene, which was recombined either with the
cDNA encoding the Py-MT antigen (pHO6MT1) or with a
mutated (Val 12) human Ha-ras gene (pHO6T1) was used for
cell transfection. Caco-2 cells transfected with the plasmids
Homer 6, pHO6MT1 or pHO6T1, were designated as Caco-
2-H, Caco-2-MT and Caco-2-T cells respectively (Chastre et
al., 1993; Delage et al., 1993). The oncogene-transfected
Caco-2-MT and Caco-2-T cells are regularly verified for
overexpression of PKC-o mRNA transcripts (Delage et al.,
1993), which is taken as an index of maintenance of
functional oncogenes in these cell lines.
Cells were routinely grown at 37°C on 100 mm diameter
dishes in a humidified incubator equilibrated with 5% carbon
dioxide using Dulbecco's modified Eagle medium (DMEM)
(4.5 gl-l glucose) supplemented with 15% fetal calf serum,
2 mM glutamine, 100 units ml-' penicillin and 100 mg ml-'
streptomycin. For all the assays reported below, the cells
were harvested at confluency.
Isolation of transmembrane PGs
Control Caco-2-H and oncogene-transfected Caco-2-MT and
Caco-2-T cells were incubated with Na235SO4 (50 mCi ml-')
for 24 h. After labelling, cell monolayers were washed twice
in ice-cold calcium- and magnesium-free phosphate-buffered
saline (PBS). An extraction protocol using a detergent cell
lysis buffer was designed to obtain cellular fractions enriched
in plasma membrane-associated PGs (Yanagishita and
Hascall, 1984). Briefly, cells were extracted and sonicated in
8 M urea, 150 mM sodium chloride, 1% Triton X-100, 50 mM
sodium acetate (pH 4.5), 5 mM EDTA, 5 mM benzamidine,
5 mM NEM and 1 mM PMSF (Yeaman and Rapraeger,
1993). The detergent extracts were then centrifuged at 600 x g
to remove insoluble material. 35S-PGs in the supernatant were
isolated by ion-exchange chromatography on DEAE-Sepha-
cel. Columns were equilibrated with extraction buffer and
eluted with a linear gradient of sodium chloride (0.05-1.0 M)
in the same buffer. Fractions were assayed for 35S-radio-
activity by scintillation counting in a LKB 1209 counter
(ACS, Amersham, UK). The peak of radioactivity eluting in
the salt gradient was dialysed extensively against 10 mM Tris-
HCl (pH 7.4) containing 0.1% Triton X-100 and supplemen-
ted with PMSF at a final concentration of 0.1 mM (Yeaman
and Rapraeger, 1993). Before hydrophobic chromatography,
aliquots of the purified PGs were diluted 20-fold to reduce
the detergent concentration.
Hydrophobic affinity chromatography
The hydrophobic properties of the detergent-extracted 35S-
PGs purified by ion-exchange chromatography were deter-
mined by gel chromatography on Octyl-Sepharose CL-4B.
Columns (2 ml) were equilibrated with 4 M guanidinium
hydrochloride (Gdn HCl)-50 mM sodium acetate (pH 7.0).
After washing with the same buffer, columns were eluted with
a 50 ml gradient of Triton X-100 (0-0.8%) in the Gdn HCl
buffer. Fractions (1 ml) were analysed for the Triton X-100
concentration by absorbance at 280 nm and for 35S radio-
activity by liquid scintillation counting.
Biochemical characterisation ofsyndecan-l
Expression of syndecan-1 in control and oncogene-trans-
fected Caco-2 cells was analysed by Northern blot and
immunoblot analyses. For Northern blot analysis, RNA
samples containing 30 ,ig of total RNA were electrophoresed
through 1% agarose-6% formaldehyde gels, blotted onto
Hybond-N nylon membranes (Amersham) and hybridised
with a mega-prime-labelled cDNA probe specific for
syndecan-1 (Saunders et al., 1989). After hybridisation, blots
were washed at 65°C to high stringency, (0.1x SSC, 0.1%
SDS), and exposed to Kodak X-Omat AR film with
intensifying screens at -80°C. RNA was quantified and
normalised by differential densitometric scanning of synde-
can-I bands vs the 28S rRNA bands (Levy et al., 1994).
For immunoblot analysis, PG-enriched fractions were
prepared from detergent extracts of cells and partially
purified as indicated previously (Inki et al., 1994). Samples
were fractionated by SDS-PAGE (2-20% gradient) in Tris
borate buffer (Jalkanen et al., 1985), and electrophoretically
transferred to Immobilon-N membranes. Membranes were
then probed with MAb 281-2, an antibody which recognises
the core protein of syndecan-1 (generous gift from Dr M
Bernfield, Harvard Medical School, Boston, MA, USA).
Detection of immunoreactive protein was performed with the
RPN Amersham enhanced chemiluminescence Western
blotting detection system.
Isolation of the syndecan-I ectodomain
The syndecan-1 ectodomain was isolated as described
(Jalkanen et al., 1987). Briefly, after a 24 h incubation with
35S-sulphate, cells were scraped into cold PBS in the presence
of proteinase inhibitors and centrifuged for 10 min at 300 g,
and the pellet was exposed to trypsin (20 mg ml-') for
10 min on an ice bath. The reaction was stopped by adding
100 mg ml-' of soybean trypsin inhibitor. After a further
centrifugation, the trypsin-cleavable ectodomain was ob-
tained in the supernatant (Rapraeger and Bernfield, 1985).
Quantification ofsyndecan-J
The syndecan-1 ectodomain was quantified by blotting on
Zeta-Probe membranes. Briefly, aliquots of trypsin-released
35S-syndecan-1 ectodomain were brought to a final concen-
tration of 8 M urea and equilibrated with loading buffer
containing 10 mM Tris-HCl, 8 M urea, 0.1% Triton X-100
(pH 8.0) and were spotted onto Zeta-Probe membranes with
a dot-blot microfiltration apparatus (Bio-Rad Laboratories),
as described (Buee et al., 1991). After passive filtration, the
membranes were extensively washed under vacuum with theSyndecan-I in oncogene-transfected Caco-2 cells
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loading buffer, then with 50 mM Tris HCl, 150 mM sodium
chloride (pH 8.0) and finally with water. The dots were cut
out and bound radiolabelled syndecan-1 ectodomain was
quantified by scintillation counting.
Glycosaminoglycan (GAG) chains of syndecan-I were
characterised by their differential susceptibility to nitrous acid
deminative cleavage or chondroitin ABC lyase degradation,
as previously reported (Levy et al., 1989). After nitrous acid
degradation of the GAGs, CS chains remain, as judged by
their sensitivity to chondroitinase digestion; alternatively,
after chondroitin ABC lyase digestion of the GAGs, HS
chains remain, identified by their susceptibility to nitrous acid
degradation. After treatment, radiosulphate incorporation
into HS and CS was quantified by spotting samples onto
Zeta-Probe membranes as described above and by counting
the corresponding membrane spots.
Gelfiltration and ion-exchange chromatography
Gel filtration of syndecan-I ectodomain on Sepharose CL-4B
(0.9 x 60 cm) was performed in 4 M Gdn HCl containing
50 mM sodium acetate, at a flow rate of 9 mlh-'. Free GAG
chains were produced from syndecan-1 ectodomain by #-
elimination with alkaline borohydride, as previously de-
scribed (Levy et al., 1986). The HS and CS GAG chain
sizes were determined after chromatography on Sepharose
CL-6B (0.9 x 60 cm) by comparing the Kay determined
experimentally with a standard curve of log Mr vs Ka, for
GAG chains of various known molecular weights (Wasteson,
1971). Void and total volumes of the sizing columns were
marked by blue dextran and phenol red respectively.
Ion-exchange chromatography of the GAG chains of the
syndecan-1 ectodomain was performed on a DEAE-Sephacel
column (1 x 3 cm). After washing the column with 50 mM
Tris-HCl, 50 mm sodium chloride (pH 6.8), elution was
performed with a linear 50 ml gradient of 50-800 mM
sodium chloride in the same buffer under a constant flow
rate of 5 ml h- . Fractions (2 ml) were collected. The
gradient was determined by conductivity measurements of
the fractions (radiometer) and radioactivity was measured.
Heparanase activity
Preparation of 35S-labelled HSfrom Caco-2-H cells Caco-2-
H cells were labelled with 35S-sulphate for 24 h. 35S-GAG
were prepared by alkaline borohydride degradation as
described above. GAGs were digested with chondroitin
ABC lyase and the degradation products were removed by
passing through a Sepharose Cl-6B column equilibrated with
4 M Gdn HCl containing 50 mM sodium acetate. The
radioactive peak in the void volume was collected, dialysed
and concentrated. This material treated with nitrous acid was
completely degraded and was thus identified as pure HS.
Cell extracts Once confluent, cell monolayers of Caco-2-H,
Caco-2-MT and Caco-2-T cells were washed 3 times with PBS
and detached from the dish by gentle shaking at 37°C in the
presence ofcalcium- andmagnesium-free PBScontaining 2 mM
EDTA. Cells were collected by centrifugation at 900 x g for
10 min at 4°C, washed 3 times with PBS and freeze-dried. The
lyophilised cells were then dispersed in 0.1% Triton X-100 and
sonicated for 30 sin anicebath(Ricoveri andCappelleti, 1986).
Protein was assayed by the method ofLowry et al. (1951) using
bovine serum albumin in 0.1% Triton X-100 as the standard.
Approximately 30 x 103 d.p.m. of35S-HS isolated fromCaco-2-
H cells were added to cell extracts (3 mgproteins) from Caco-2-
H, Caco-2-MT or Caco-2-T cells. All digestions were
performed at 37°C in a 0.1 M sodium phosphate buffer
(pH 6.0) containing 15 mM D-saccharic acid 1,4 lacton, an
inhibitor of P-glucuronidase (Ricoveri and Cappelleti, 1986).
Digestions were carried out in duplicate using a boiled extract
as a control. At the end of incubation, the mixture was
centrifuged at 10000 x g for 5 min and the supernatant was
applied to a Sepharose Cl-6B column, as described above.
Intact cells Equal amounts (30 x 103 d.p.m.) of 35S-HS from
control Caco-2-H cells were added to confluent cell
monolayers of Caco-2-H, Caco-2-MT or Caco-2-T cells.
The medium was buffered by adding 1 M Hepes (pH 7.4) to a
final concentration of 10 mM. The cells were incubated for
the indicated times with gentle-shaking. At the end of
incubation, the medium was harvested, centrifuged at
10 000 xg for 5 min and fractionated, as described for cell
extracts.
Statistical analysis
Results are means+s.d. for the indicated numbers of
experiments with different cell preparations.
Results
Membrane-anchored PGs
The PGs from control and oncogene-transfected Caco-2
cells were examined for the presence of lipophilic moieties
by hydrophobic chromatography on Octyl-Sepharose CL-
4B, a procedure currently used to identify PG species that
are integral components of the plasma membrane.
Chromatography of detergent-extracted PGs generated
two sulphate-containing peaks (Figure 1). The first peak,
which eluted before the beginning of the gradient,
constituted the unbound fractions. The second peak,
requiring a detergent-containing buffer to be displaced
from the column, contained 35S-labelled PGs which bound
to Octyl-Sepharose through hydrophobic interactions. This
bound material comprised the lipophilic PGs. In control
Caco-2-H cells (Figure la), 57.6% of the total 35S-labelled
PGs bound to the column, and the hydrophobic PG
fraction eluted at 0.14% Triton X-100. In contrast, in the
oncogene-transfected Caco-2-MT cells (Figure lb) and
Caco-2-T cells (Figure Ic), only 40.5% and 37.2% of the
total 35S-labelled PGs bound to the column, and the
hydrophobic PG fractions eluted at Triton X-100 concen-
trations of 0.11% and 0.09% respectively. These results
indicate that expression of Ha-ras or Py-MT oncogenes in
Caco-2 cells induced a decrease in the amount of
membrane-anchored PGs. As indicated in Table I, this
decrease was selectively accounted for by a decrease in
syndecan-1 since the amount of the other lipophilic PGs
was not modified in oncogene-transfected Caco-2-MT and
Caco-2T cells.
Syndecan-J expression
Among the membrane-anchored PGs, syndecan-I is known
to play a central role in the maintenance of the epithelial
phenotype. We therefore examined the expression of this PG
in Caco-2 cells to determine ifit was altered by Ha-ras or Py-
MT oncogenes. Figure 2 shows the results of Northern blot
analysis using a cDNA probe specific for syndecan-1
(Saunders et al., 1989). In control Caco-2 cells, two mRNA
transcripts of 2.6 and 3.4 kb were detected (Figure 2a), in
accordance with the results reported for other cell types
(Saunders et al., 1989; Kirjavainen et al., 1993; Inki et al.,
1994). In oncogene-transfected Caco-2-MT and Caco-2-T
cells, syndecan-1 mRNA transcripts were present in a relative
abundance similar to that observed in Caco-2-H cells, as
determined by densitometric scanning of the Northern blots
and normalisation ofthe results with respect to the 28S signal
(Figure 2a). These results indicate that neither Ha-ras nor
PY-MT oncogenes modified the amount of syndecan-1
mRNA.
Figure 2b shows the results of immunoblot analysis using
an anti-syndecan-1 antibody (Jalkanen et al., 1985). In all
three cell lines, this antibody recognised a core protein of
approximately 70 kDa, which is in accordance with the
published molecular mass of syndecan-1 core proteinSyndecan-l in oncogene-transfected Caco-2 cells
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Table I 35S incorporation into lipophilic PGs
Total membrane-
anchored Syndecan-I Other
Cell line PG(c.p.m.) (c.p.m.) (c.p.m.)
Caco-2-H 23 205+2 575 17 400+1 635 5 800+555
Caco-2-MT 15 650+2 065 9 565+945 6 085+630
Caco-2-T 14 370+2 125 8 710+920 5 660+690
Control and oncogene-transfected Caco-2 cells were labelled with
Na235SO4. 35S incorporation into total membrane-anchored PGs was
determined as indicated in Figure 1. 35Sincorporation into syndecan-l
was determined after mild trypsin treatment of the cells. Other,
lipophilic PGs expressed at the cell surface as trypsin-resistance PGs.
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Figure 1 Hydrophobic affinity chromatography of detergent-
extracted PGs. DEAE-purified 35S-labelled PGs from control
Caco-2-H (a) and oncogene-transfected Caco-2-MT (b) or Caco-
2-T (c) cells were chromatographed on Octyl-Sepharose CL-4B.
Columns were equilibrated with 4M Gdn HC1-50mM sodium
acetate (pH 7.0) and eluted with a linear gradient of 0-0.8% (v/v)
Triton X-100 in the same buffer. Fractions (1 ml) were analysed
for Triton X-100 concentration by absorbance at 280nm and
monitored for radioactivity.
(Jalkanen et al., 1985; Sanderson et al., 1992b; Inki et al.,
1994). However, relative to control Caco-2-H cells, both
oncogene-transfected Caco-2-MT and Caco-2-T cells exhib-
ited a decrease in the amount of syndecan-I core protein as
determined by densitometric scanning of the Western blots
(Figure 2b). Thus, our results provide clear evidence that
oncogenic p2lras and PY-MT/pp60c-src decreased syndecan-1
protein expression without modifying syndecan-2 mRNA
level.
Specific activity ofsyndecan-J ectodomain and its HS and CS
GAG side chains
The 35SO4-labelled ectodomain of syndecan-1 from control
and oncogene-transfected cells was isolated as described in
Materials and methods, and incorporated radioactivity was
Figure 2 Northern blot and Western blot analyses of syndecan-
1. In a, 30jug of total RNA isolated from control Caco-2-H and
oncogene-transfected Caco-2-MT or Caco-2-T cells were size-
fractionated in a 1% agarose/formaldehyde gel and blotted onto
Hybond-N membrane. The membrane was hybridised with a
cDNA probe specific for syndecan-l (Saunders et al., 1989), and
then with a 28S rRNA probe. In b, samples of PG-enriched
fractions were fractioned by SDS-PAGE (2 to 20% gradient)
and transferred onto an Immobilon-N membrane. The membrane
was then probed with MAb 281-2, and immunoreactive protein
was visualised using enhanced chemiluminescence. The band
representing the core protein of syndecan-l is indicated by an
arrow. Corresponding molecular weight markers in kDa are
shown on the left.
measured by dot-blot assay. As reported in Table II, the
specific activity of the syndecan-1 ectodomain (expressed as
d.p.m. mg-1 of protein) was markedly lower in oncogene-
transfected Caco-2-MT and Caco-2-T cells (42 380+ 5600
and 30 240+4570 respectively), than in control Caco-2-H
cells (151 760+ 14 115).
To compare 35S-sulphate distribution in the HS and CS
side-chains of syndecan-l in the three cell lines, labelled
syndecan-1 ectodomains were isolated from Caco-2-H, Caco-
2-MT and Caco-2-T cells and subjected to chondroitin ABC
lyase or nitrous acid degradation, and the remaining HS or
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CS chains were examined for their specific radioactivity. In
the three cell lines, the syndecan-1 ectodomain consisted
mainly of HS chains but also possessed some CS chains
(Table II). In control Caco-2-H cells, most of the total 35S-
sulphate incorporated into the syndecan-I ectodomain (i.e.
87.9+2.8%) was degraded with nitrous acid, indicating that
it consisted of HS chains, whereas CS chains only accounted
for 12.1 +2.8%, as determined by sensitivity to chondroitin
ABC lyase. In contrast, in oncogene-transfected Caco-2-MT
and Caco-2-T cells, the proportions of "5S-sulphate incorpo-
rated into HS chains decreased to 74.1+3.6% and
64.6+5.8% of total "5S-labelling respectively, whereas the
respective proportions of 35S-sulphate incorporated into CS
chains rose to 25.9+3.6% and 35.4+5.8%. These data
provide clear evidence that the functional insertion of Ha-ras
or Py-MT oncogenes in Caco-2 cells markedly lowered the
specific activity of the syndecan-I ectodomain, and con-
comitantly reduced the HS/CS specific activity ratio.
Polyanionic properties of GAG side-chains in the syndecan-I
ectodomain
To establish the basis of the post-translational modifications
of the syndecan-l ectodomain in oncogene-transfected Caco-
2-MT and Caco-2-T cells, we examined two major
characteristics of their GAG side-chains: the degree of
sulphation and molecular mass.
We first determined the extent of sulphation of the
syndecan-l GAG side-chains to see if it was modified by
oncogene transfection. For this purpose, the polyanionic
properties of the "S-labelled GAGs released from the
syndecan-1 ectodomain by alkaline borohydride were
investigated by ion-exchange chromatography on DEAE-
Sephacel (Figure 3). GAGs from Caco-2-MT and Caco-2-T
cells (Figure 3b and 3c) bound less tightly to the column than
GAGs from control Caco-2-H cells (Figure 3a), as indicated
by their elution at lower sodium chloride concentrations than
those required for elution of GAGs from control Caco-2-H
cells (0.47 M and 0.40 M vs 0.56 M). These results indicate a
lower degree of sulphation of syndecan-l GAG side-chains in
oncogene-transfected cells than of the corresponding chains
in control cells.
Size analysis ofsyndecan-1 ectodomain
35S-labelled syndecan-I ectodomains isolated from control
and oncogene-transfected Caco-2 cells were analysed on
sepharaose CL-4B column (Figure 4). Syndecan-I from
Table II Specific activity ofsyndecan-1 ectodomain and its HS and
CS GAG side-chains in control and oncogene-transfected Caco-2
cells
Syndecan
ectodomain HS CS
(d.p.m. mg-' (d.p.m. mg-' (d.p.m. mg-'
Cell line ofprotein) ofprotein) ofprotein)
Caco-2-H 151 760+14 115 133 550+13 620 18 210+2 385
(100%) (87.9+2.8%) (12.1±2.8%)
Caco-2-MT 42 375+5 600 31 400+4 430 10 975+1 700
(100%) (74.1 ±3.6%) (25.9±3.6%)
Caco-2-T 30 230+4 570 19 530+3 280 10 700+ 1 840
(100%) (64.6±5.8%) (35.4±5.8%)
Cells were metabolically labelled for 24 h with 35S-sulphate. The
syndecan-1 ectodomain from control Caco-2-H and oncogene-
transfected Caco-2-MT or Caco-2-T cells were collected by mild
trypsinisation. The radiolabel in the syndecan ectodomain was
quantified by binding to Zeta-Probe membranes as described in
Materials and methods. Radiolabel in HS and CS was determined by
specific susceptibility to nitrous acid or chondroitin ABC lyase
respectively, and was quantified as for the intact syndecan-1
ectodomain. Results are expressed as d.p.m. mg7l of protein.
Numbers in brackets represent percentage of total 35S-sulphate
incorporation in the syndecan ectodomain. Each value represents the
mean+s.d. offive experiments.
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Figure 3 Ion-exchange chromatography on DEAE-Sephacel of
GAG chains from syndecan-1. 5SO4-labelled GAGs released
from syndecan-1 ectodomain of control Caco-2-H (a) and
oncogene-transfected Caco-2-MT (b) or Caco-2-T (c) cells by
alkaline borohydride were applied to a DEAE-Sephacel column
(1 x 2cm). After extensive washing of the column with a buffer
containing 50mM Tris-50mm sodium chloride (pH6.8), the
elution was performed with a linear gradient of 50mM-800mM
sodium chloride in the same buffer. The resulting 2ml fractions
were collected and analysed for radioactivity.
control Caco-2-H cells eluted as a peak with a Kay of 0.50
(Figure 4a), whereas syndecan-1 from transfected Caco-2-MT
and Caco-2-T cells eluted as a peak with Kay values of 0.62
(Figure 4b) and 0.66 (Figure 4c) respectively. These results
show that the ectodomain of syndecan-I synthesised by Ha-
ras or Py-MT oncogene-transfected Caco-2 cells exhibited
smaller hydrodynamic sizes than that of syndecan-1 from
control Caco-2-H cells.
GAG chain length ofsyndecan-J ectodomain
To determine whether the lower relative molecular mass of
syndecan-l ectodomain in transfected Caco-2 cells was due to
a reduction in its GAG chain length, "S-labelled ectodomains
were subjected to alkaline fl-elimination and then to
degradation with either chondroitin ABC lyase or nitrous
acid. The resulting HS or CS chains were chromatographed
on Sepharose CL-6B and their respective Kay values in Caco-
2-MT and Caco-2-T cells were 0.60 and 0.65 for HS chains,
and 0.53 and 0.56 for CS chains (Table III). In control Caco-
2-H cells, the Kay value was 0.45 for HS chains and 0.50 for
CS chains. Thus, the syndecan-I synthesised by oncogene-
transfected Caco-2 cells contained HS and CS chains of a
smaller hydrodynamic size than the syndecan-I synthesised
by control Caco-2-H cells (Table III).Syndecan-1 in oncogene-transfected Caco-2 cells
P Levy et a!
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Heparanase degradative activity in oncogene-transfected Caco-
2-MT and Caco-2-T cells
The reduced hydrodynamic size of the HS chains of the
syndecan-1 ectodomain in oncogene-transfected Caco-2 cells
led us to suspect HS degradation by active heparanase in
these cells. To test this hypothesis, intact control Caco-2-H
cells and oncogene-transfected Caco-2-MT and Caco-2-T
cells, as well as cell extracts from all three cell lines, were
compared for heparanase degradative activity using 35S-
labelled HS extracted from control Caco-2-H cells as a
substrate (see Materials and methods).
Incubations were carried out at 370C for 3, 6, 18 and
30 h. The degradation products were analysed by gel
chromatography on Sepharose Cl-6B and monitored by
scintillation counting. The first set of experiments, carried
out with intact Caco-2 cells, showed that neither Caco-2-H
cells nor oncogene-transfected Caco-2-MT and Caco-2-T
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cells contained significant heparanase activity, whatever the
incubation time studied (data not shown). With cell extracts
of the three cell lines, no appreciable degradation was
observed after short incubation periods (3 h or 6 h). By
contrast, after 18 h incubation we detected heparanase
activity which degraded the HS in the cell extracts from
the oncogene-transfected Caco-2 cells. The presence of this
activity was indicated by an incompletely resolved, slowly
eluting peak of lower molecular weight species than in the
control Caco-2-H cells, which displayed no heparanase
activity. The elution patterns of Caco-2-MT and Caco-2-T
cells after incubation for 18 h are compared in Figure 5b
and 5c with the pattern obtained for the control cell extracts
(Figure 5a). However, after an even longer incubation period
(30 h), no further degradation was observed (data not
shown). These results indicate the presence of heparanase
degradative activity in cell extracts from oncogene-trans-
fected Caco-2 cells.
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Figure 4 Sepharose Cl-4B chromatography of syndecan-1. 35S-
sulphate labelled syndecan- ectodomains from control Caco-2-H
(a) and oncogene-transfected Caco-2-MT (b) or Caco-2-T (c) cells
were applied to a Sepharose CL-4B column (0.9 x 60cm). Elution
was performed with a 4M Gdn HC1-50mm sodium acetate
buffer (pH 5.8) containing 0.5% (w/v) CHAPS and protease
inhibitors. Fractions of 0.5ml were collected and analysed for
radioactivity.
Figure 5 Heparanase degradative activity in oncogene-trans-
fected Caco-2 cells. After a 24h labelling, 35S-labelled HS from
control Caco-2-H cells was prepared by alkaline borohydride
degradation. This 35S-HS (30x 103d.p.m) was incubated for 18h
in the presence of Caco-2-H (a), Caco-2-MT (b) and Caco-2-T (c)
cell extracts (3 mg proteins) and then fractionated on a 0.9 x 60cm
Sepharose Cl-6B equilibrated with 4M Gdn HCI - 50mM sodium
acetate (pH7.0), at a flow rate of 9mlh-1.
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Table III Approximate molecular mass of GAG side chains of the
syndecan-1 from control and oncogene-transfected Caco-2 cells
HS CS
Cell line Kava kDab Kava kDab
Caco-2-H 0.45 28.0 0.50 24
Caco-2-MT 0.60 12.5 0.53 19
Caco-2-T 0.65 9.0 0.56 16
aKay values displayed are for the peak elution fractions on
Sepharose Cl-6B columns. bThe approximate kDa of HS and CS
chains was calculated on the basis ofa standard curve according to the
method ofWasteson (1971).
Discussion
The present study was designed to examine the alterations in
syndecan-1 during the tumorigenic progression induced by
oncogenic p21raS and pp60c-src in human colonic epithelial
cells. To this end, we used Caco-2 cells transfected either with
an activated (Val 12) human Ha-ras gene or with the cDNA
encoding the Py-MT antigen, a constitutive activator of the
tyrosine kinase of pp6Oc.src.
One important observation made in our study is that both
oncogene-transfected Caco-2 cell lines displayed similar
alterations in their syndecan-1, although each expressed a
specific oncoprotein. In a recent report, we provided clear
evidence that the Py-MT oncogene caused a constitutive
increase in the activity of p2lras in Caco-2-MT cells which
was almost identical to that caused by the oncogenic
activation of p2lras in Caco-2-T cells (Baron-Delage et al.,
1994). Therefore, in human colonic Caco-2 cells, p2lraS lies
downstream of Py-MT/pp60c-src in the same signal transduc-
tion pathway, as reported for another cell type (Pickett and
Gutierrez-Hartmann, 1994).
Here, we show that oncogenic p21r-s and Py-MT/pp60csrc
induced a decrease in syndecan-1 expression at the protein
but not the mRNA level. A similar finding was yet reported
by others for the Ha-ras-transformed epithelial NOG-8 cell
line and was suggested to result from decreased mRNA
translation in oncogene-transformed cells (Kirjavainen et al.,
1993). Along with decreased syndecan-1 expression, ras- and
PY-MT-transfected Caco-2 cells exhibited a dramatic
activation of their tumorigenic potential in nude mice but
failed to become invasive as previously determined by using
an in vitro invasion assay (Chastre et al., 1993). In fact,
several arguments support the notion that the invasiveness of
transformed cells is correlated with a complete down-
regulation of syndecan-1 expression: (1) In vivo studies of
syndecan-1 expression in transformed keratinocyte cell lines
have shown that when cells were injected into nude mice,
poorly differentiated areas, i.e. the most invasive areas within
the tumour, were devoid of syndecan-1 expression at the
protein and mRNA levels (Inki et al., 1992); (2) S115 mouse
mammary tumour cells that exhibited malignant growth
behaviour lacked syndecan-1 gene expression but lost their
malignant growth behaviour after the re-expression of
syndecan-1 (Leppa et al., 1992); (3) In vitro studies using B
lymphoid cells have shown that syndecan-I must be lost
before cells can invade the extracellular matrix (Liebersbach
and Sanderson, 1994). In the light of these findings which
point to an inverse relationship between syndecan-1
expression and the invasive potential of transformed cells,
one may wonder whether the failure of ras or Py-MT
oncogenes to endow Caco-2 cells with the invasive phenotype
may be connected with their inability to repress completely
syndecan-1 expression in these cells.
Initial studies provided evidence for a close correlation
between syndecan mRNA and its immunoreactive protein
expression in healing wounds or during tooth organogenesis,
thus suggesting that the regulation of syndecan expression
occurs at the transcriptional level (Elenius et al., 1991; Vainio
et al., 1991). However, more recent papers provided
experimental arguments indicating that syndecan-1 expres-
sion is regulated at the translational level (Sanderson et al.,
1992; Vainio et al., 1992; Kirjavainen et al., 1993). In the
present study, we provide clear evidence that Ha-ras and PY-
MT oncogenes alter syndecan-1 expression at both the
translational and post-translational levels. Caco-2-MT and
Caco-2-T cells indeed showed a decrease in syndecan-1
protein but not mRNA expression and also exhibited
alterations in syndecan-l ectodomain. These alterations
consisted of a decrease in the length and degree of
sulphation of the GAG chains attached to the protein core
together with modification of the GAG composition.
Although the main GAG of the syndecan-l ectodomain in
control and oncogene-transfected Caco-2 cells consists of HS,
a higher proportion of CS was observed in Caco-2-MT and
Caco-2-T cells. In agreement with our results, previous
authors reported that GAGs isolated from colon tumours
contain larger amounts of CS than those from normal
colonic mucosa (Tozzo and Wight, 1982; lozzo et al., 1989).
We present here, as far as we know, the first evidence for
altered glycosylation of syndecan-I associated with malignant
progression in human colonic epithelial cells. Other studies
have shown that the interactions of syndecans with
extracellular matrix components depend on ectodomain
glycosylation or sulphation (Sanderson et al., 1994), strongly
suggesting a central role for syndecan in cell-matrix
adhesion. In the light of these findings, our results are
significant, and the post-translational modifications of
syndecan-1 in Ha-ras- and Py-MT-transfected Caco-2 cells
might provide Caco-2-MT and Caco-2-T cells with a
mechanism that would allow the loosening of their
attachment to the extracellular matrix and maintain their
growth.
The first step in the development of cancer is uncontrolled
cell growth. The next critical step is the transition of the
tumour from mere growth to invasion and metastasis. During
this transition, a series of genetic and molecular events causes
tumour cells to increase their production and activation of
the enzymes that cleave the extracellular matrix. Activity that
degrades ECM components is mediated by a variety of
proteases and endoglycosidases, including the plasmin/
plasminogen activator family of serine proteases, the matrix
metalloproteinases and the heparanases, which are specific
HS PG-degrading endoglycosidases (Stetler-Stevenson et al.,
1993). The present results show that oncogene-transfected
Caco-2 cells were able to degrade purified HS, thus reflecting
the presence of heparanase activity in these cells. However,
this activity fails to be secreted and shows only limited levels.
Therefore, the decrease in HS chain size ofsyndecan-I cannot
be solely accounted for by the presence of the heparanase
activity and probably also reflects the synthesis by the
oncogene-transfected Caco-2 cells of smaller HS chains on
the same core protein.
Recent advances in the understanding of HS PGs
implicate them as important participants in cell signalling.
At the cell surface, syndecan may transduce ECM-
cytoskeletal actin-mediated signals essential for cell growth.
The conserved cytoplasmic domain of syndecans could
transmit signalling, directly or indirectly, by specifically
interacting with the membrane and cytoplasmic transduction
systems. In addition, syndecan may also mediate signalling
through interaction with cytoskeletal proteins (Rapraeger,
1993; Carey et al., 1994). In this connection, Rapraeger
speculated that the formation of the syndecan/FGF/tyrosine
kinase receptor complex results in phosphorylation of the
syndecan itself, thus influencing its interaction with the
cytoskeleton or with other receptors such as the cadherins,
and thereby directly affecting cell shape and behaviour
(Rapraeger, 1993).
In conclusion, our results demonstrate that the dramatic
activation of the tumorigenic potential induced by oncogenic
p2lras or Py-MT/pp60c-src in Caco-2 cells altered syndecan-I
expression at the protein but not the mRNA level, and
induced marked alterations in the syndecan- 1 ectodomain,Syndecan-l in oncogene-transfected Caco-2 cells $rA P Levy et al
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thus indicating that these oncoproteins influence the
translational regulation and the post-translational machinery
responsible for syndecan-1 processing. These alterations may
be critical for altered cell-matrix adhesion properties and for
the malignant growth of the oncogene-transfected Caco-2
cells.
Abbreviations
Py-MT, polyoma middle T; PG, proteoglycan; GAG, glycosami-
noglycan; HS, heparan sulphate; CS, chondroitin sulphate; ECM,
extracellular matrix; PMSF, phenylmethylsulphonyl fluoride;
NEM, N-ethylmaleimide; EDTA, ethylene diamine tetraacetic
acid; PBS, phosphate-buffered saline; Gdn HC1, guanidinium
hydrochloride; SDS, sodium dodecyl sulphate; cDNA, comple-
mentary DNA.
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